Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR A1912

Next Previous
Drug Profile

SHR A1912

Alternative Names: SHR-A1912

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported B-cell lymphoma

Most Recent Events

  • 24 Apr 2025 Phase-III clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT06929624)
  • 16 Apr 2025 Suzhou Suncadia Biopharmaceuticals plans phase-III trial for Diffuse large-B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (Parenteral, injection) in April 2025 (NCT06929624)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in China (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top